التفاصيل البيبلوغرافية
| العنوان: |
Association of sex and systemic therapy treatment outcomes in psoriasis: a two‐country, multicentre, prospective, noninterventional registry study*. |
| المؤلفون: |
Maul, J.‐T., Augustin, M., Sorbe, C., Conrad, C., Anzengruber, F., Mrowietz, U., Reich, K., French, L.E., Radtke, M., Häusermann, P., Maul, L.V., Boehncke, W.‐H., Thaçi, D., Navarini, A.A. |
| المصدر: |
British Journal of Dermatology; Dec2021, Vol. 185 Issue 6, p1160-1168, 9p |
| مصطلحات موضوعية: |
TREATMENT effectiveness, PSORIASIS, PATIENT reported outcome measures, QUALITY of life |
| مستخلص: |
Summary: Background: Few systematic data on sex‐related treatment responses exist for psoriasis. Objectives: To evaluate sex differences with respect to systemic antipsoriatic treatment. Methods: Data from patients with moderate‐to‐severe psoriasis in the PsoBest or Swiss Dermatology Network of Targeted Therapies (SDNTT) registries were analysed. Treatment response was defined as achieving a ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75) or PASI ≤ 3 at treatment months 3, 6 and 12, supplemented by patient‐reported outcomes [i.e. Dermatology Life Quality Index (DLQI) ≤ 1 and delta DLQI ≥ 4]. Results: In total, 5346 patients registered between 2007 and 2016 were included (PsoBest, n = 4896; SDNTT, n = 450). The majority received nonbiological treatment (67·3% male, 69·8% female). Women showed slightly higher PASI response rates after 3 (54·8% vs. 47·2%; P ≤ 0·001), 6 (70·8% vs. 63·8%; P ≤ 0·001) and 12 months (72·3% vs. 66·1%; P ≤ 0·004). A significantly higher proportion of women achieved a reduction in DLQI ≥ 4 [month 3: 61·4% vs 54·8% (P ≤ 0·001); month 6: 69·6% vs. 62·4% (P ≤ 0·001); month 12: 70·7% vs. 64·4% (P ≤ 0·002)]. Regarding PASI ≤ 3, women on biologics showed a significantly superior treatment response compared with men at 3 (57·8% vs. 48·5%; P ≤ 0·004) and 6 months (69·2% vs. 60·9%; P ≤ 0·018). Women in the nonbiological treatment group had a significantly better treatment response (PASI response, PASI 75 and PASI ≤ 3) over 12 months compared with men. Conclusions: We provide evidence that women experience better treatment outcomes with systemic antipsoriatic therapy than men. What is already known about this topic?Psoriasis is a stigmatizing disease that often affects females more negatively than males.Women show a higher burden of disease in psoriasis.It is largely unknown whether there are differences in response to systemic treatment according to sex. What does this study add?Women demonstrated a significant higher overall response than men for the totality of drugs studied.Women showed a significantly higher Psoriasis Area and Severity Index and Dermatology Life Quality Index response than men. Linked Comment: P. Wolf. Br J Dermatol 2021; 185:1088–1089. Plain language summary available online [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
